We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
(-34%)
Cap. Flow
-$1.01B
Cap. Flow
% of AUM
-34.35%
Top 10 Holdings %
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Monte Rosa Therapeutics
GLUE
|
+$65.1M |
| 2 |
Biomea Fusion
BMEA
|
+$56M |
| 3 |
JBIO
Jade Biosciences
JBIO
|
+$46.4M |
| 4 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
+$46M |
| 5 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$42.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$76.5M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$52.4M |
| 3 |
Novavax
NVAX
|
+$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$43.6M |
| 5 |
Omeros
OMER
|
+$35.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.38% |
| 2 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| – | – |
-1,000,000
| Closed | -$136M |
|
|
GRCL
127
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| – | – |
-125,000
| Closed | -$1.93M |
|
|
PNT
128
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – |
-500,000
| Closed | -$5.25M |
|
|
ALBO
129
DELISTED
Albireo Pharma Inc
ALBO
| – | – |
-500,000
| Closed | -$17.6M |
|
|
BLSA
130
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| – | – |
-500,000
| Closed | -$5.29M |
|
|
CCXI
131
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-850,000
| Closed | -$43.6M |
|
|
ARNA
132
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-20,000
| Closed | -$1.39M |
|
|
KDMN
133
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-750,000
| Closed | -$2.92M |
|
|
VSPRU
134
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
| – | – |
-400,000
| Closed | -$4.62M |
|
|
BHVN
135
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-200,000
| Closed | -$13.7M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.
- Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
- Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
- Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
- Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
- Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
- Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
- Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.
Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.